Imugene: Serious inroads – a highly successful cancer drug trial

(3:7)

The First Human Trial Of Virus That Kills Cancer | Imugene Vaxinia Explained

(9:40)

Imugene CEO And COO Speak With JustStocks Video After Promising Results In Blood Cancer Trial

(7:17)

First Patient dosed in Imugene's PD1-Vaxx Combination Trial

(4:)

Imugene (ASX:IMU) | JMM \u0026 éthica Capital Innovation Interview \\ May 2024

(5:4)

First cohort 3 patient dosed in CHECKvacc trial

(4:45)

How Imugene is Turning Viruses into Cancer-Fighting Heroes!

(32:27)

Imugene releases final data from Phase 2 HER Vaxx study

(5:30)

Interview With The CF33 Oncolytic Virus Inventor - Imugene (IMU)

(20:11)

Island where people live longer than anyone on earth | 60 Minutes Australia

(12:52)

A Californian Cancer Killer Professor Yuman Fong and his work with Imugene

(26:16)

Imugene (ASX: IMU) – The ‘Holy Grail’ Of Cancer Treatment…?! | ASX CEO Interview 🚀📈

(20:37)

Imugene featured on Fox Business's 'Trending Today' as a trailblazer in the biotechnology industry.

(4:53)

Imugene (ASX: IMU) - Discussing IMU's 2022 Biotech Opportunity

(20:57)

Investor Presentation post ASX news: Imugene and Eureka Therapeutics onCARlytics Collaboration

(26:56)

Investor webinar: Azer-cel trial update, September 2024

(25:35)

Silence ICU management or AI in ICU

(1:2:54)

Etherio

(8:29)

Imugene Science Series With Dr Yuman Fong - November 2024

(20:20)

Breakthrough therapy entering clinical trials. Cancer killing virus by Imugene is sheer genius!!

(13:40)

Imugene CEO talks 2024 milestones and oncolytic opportunities

(4:28)

Imugene welcomes dosing of first patient in nextHERIZON Phase 2 clinical trial

(5:20)

Imugene thrilled as first patients dosed in VAXINIA MAST combination study

(5:15)

Imugene talks dose escalation for CHECKvacc's City of Hope trial

(6:12)

Imugene bringing effective new treatments and options to cancer patients

(11:25)

Biotech Unlocked - IMUGENE ASX:IMU

(18:36)

'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

(4:51)

Imugene Officially Announce Their HER-Vaxx Trial Results

(8:59)

Imugene talks ABL partnership for VAXINIA and $80 million institutional capital raise

(4:50)